skip to primary navigationskip to content

GeneAdviser partners with Birmingham Women’s Hospital to make personalised medicine more accessible

last modified Sep 29, 2016 10:46 AM
The largest genetics laboratory in the NHS brings to the platform their solid tumour sequencing, enabling clinicians to give an individual approach to their patients, tailored to their tumour’s genetic makeup.
GeneAdviser partners with Birmingham Women’s Hospital to make personalised medicine more accessible

 GeneAdvisor's CEO Jelena Aleksic (left) and CTO Robert Stojnic (right)

GeneAdviser is bringing the expertise of Birmingham Women’s Hospital to their ordering platform, where healthcare professionals can now order tests for genetic sequencing of tumour samples, screening for those changes in the tumour that may require clinical action.

Each tumour has a different genetic makeup, which makes it react to therapies very differently. By analysing and monitoring the presence of genetic sequences in a tumour, patients can be prescribed more targeted treatment and screening.

Dr Jelena Aleksic, GeneAdviser’s CEO, commented: “Birmingham Women’s Hospital combines outstanding and comprehensive genetics research and clinical expertise, making it an internationally renowned clinical laboratory. We are delighted to make their excellent genetic testing more accessible to doctors worldwide, helping them provide better care for their patients.”

Professor Michael Griffiths, the Birmingham Women’s Hospital Genetics Laboratory Director, added: "We are excited to join forces with GeneAdviser to facilitate worldwide access to our genetic test portfolio.  As the largest NHS genetics laboratory we already work closely with clinicians across the UK and internationally, and GeneAdviser will allow them to easily order the genetic  tests they need for their patients, whilst streamlining administrative processes for our staff."

Their partnership also expands beyond solid tumour sequencing, bringing forward a selection of high quality genetic tests in oncology and other medical specialties. Other tests from Birmingham Women’s Hospital include their Lucina NIPT (non invasive prenatal testing), a highly accurate genetic prenatal testing that screens for trisomies such as Down syndrome using a single maternal blood sample.

RSS Feed Latest news

Spotlight on Mursla

Feb 03, 2019

Cancer is one of the most challenging global issues an entrepreneur could choose to tackle. But Pierre Arsène and Victor Serdio are doing just that with their company Mursla. Based at ideaSpace West, Mursla is developing a breakthrough technology for early cancer detection using liquid biopsies, offering a less invasive and more responsive approach to diagnosis, treatment and cure. To mark World Cancer Day on the 4th February, we asked Pierre to explain more about Mursla and the bold ideas and enthusiasm driving this bright company.

LESSONS FROM A FOUNDER: What's Your 2019 Startup Goal?

Jan 30, 2019

For many of us, a new year often starts with an optimistic resolution to change – join the gym, write a book, travel perhaps. But if you’re running a startup, January is a great time to assess your company’s development and set fresh goals for the coming year. We asked four founders at ideaSpace to reflect on progress and share their area of focus for 2019.

GeoSpock Lands £10 Million in Additional Funding 

Jan 09, 2019

ideaSpace alumni and extreme data specialists, GeoSpock, have secured an extra  £10 million in funding. The latest round was led by Cambridge Innovation Capital (CIC) jointly with Parkwalk Advisors and Japanese firms Global Brain and 31Ventures. Japanese data tech company KDDI Supership joined as a strategic investor. Investment was also secured from existing investor, Jonathan Milner.

A Breath Test Could Detect Early Cancer Signs

Jan 06, 2019

CRUK and ideaSpace City members, Owlstone Medical, have launched a new trial to discover whether it's possible to detect early stage cancer symptoms from a person's breath.

Petagene secure $2.1 Million in Funding 

Jan 03, 2019

2019 is off to a great start for the Petagene team who have been awarded $2.1 million in additional funding. The latest round was lead by U.S. venture firm Romulus Capital, with collaboration from other unnamed investors in London and Silicon Valley, bringing the total funding awarded to $3.2 million.

View all news